| A Medical Research Council Randomised Trial to Compare Aspirin versus Hydroxyurea/Aspirin in Intermediate Risk Primary Thrombocythaemia and Hydroxyurea/Aspirin versus Anagrelide/Aspirin in High Risk Primary Thrombocythaemia |
| Trial Code: | ISRCTN72251782 |
| Type: | Phase III |
| Status: | Open |
| Link: | http://www.controlled-trials.com/mrct/trial/THROMB... |
| Website: | http://212.219.75.230/scripts/ukcccr/ibmhpj/bin/DisDetail.exe?MRC%20PT1:0:user:guest |
| 1. To assess the incidence of vascular occlusion in low risk patients while receiving aspirin only. 2. To determine whether hydroxyurea reduces vascular occlusive events when added to aspirin in intermediate risk patients. 3. To determine whether anagrelide reduces vascular occlusive events as effectively as hydroxyurea in high risk patients 4. To determine whether anagrelide is as effective as hydroxyurea in reducing elevated platelet counts in high risk patients. 5. To assess the effect of the treatment modalities on quality of life. 6. To assess whether in high and intermediate risk patients treatment modality alters the risk of leukaemia and myelofibrotic transformations. |
